S Mahner
Overview
Explore the profile of S Mahner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgmann M, Hermelink K, Lotz A, Schlager V, Kolben T, Seifert C, et al.
Arch Gynecol Obstet
. 2025 Feb;
PMID: 39939463
Purpose: Due to increasing life expectancy and demographic trends in recent years, the specific needs of elderly patients have gained more and more attendance. The aim of this study is...
2.
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol
. 2024 Feb;
35(3):248-266.
PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
3.
Topalov N, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus F, et al.
Sci Rep
. 2023 Dec;
13(1):22620.
PMID: 38114558
Actin beta-like 2 (ACTBL2) was recently identified as a new mediator of migration in ovarian cancer cells. Yet, its impact on tumor-infiltrating and thus migrating leukocytes (TILs) remains to date...
4.
Tremmel E, Starrach T, Buschmann C, Trillsch F, Kolben T, Mahner S, et al.
Arch Gynecol Obstet
. 2023 Dec;
309(4):1227-1236.
PMID: 38078931
Purpose: Ectopic pregnancies include cesarean scar (CSP), cornual and cervical pregnancies. Various treatment modalities have been- described, but no standardized procedure has been defined so far. The aim of our...
5.
Buechel J, Monod C, Alba Alejandre I, Ninke T, Hoesli I, Starrach T, et al.
J Gynecol Obstet Hum Reprod
. 2023 Apr;
52(6):102597.
PMID: 37087046
Objective: Amniotic fluid embolism (AFE) is a rare life-threatening complication in obstetrics, but the diagnosis lacks a consensual definition. The objective of this study was to compare two different AFE...
6.
Kraus F, Topalov N, Deuster E, Hysenaj I, Mayr D, Chelariu-Raicu A, et al.
J Cancer Res Clin Oncol
. 2022 Jun;
149(6):2501-2511.
PMID: 35751684
Purpose: Despite recent advances in the treatment of ovarian cancer (OC), long-term remissions remain scarce. For a targeted approach, prognostic markers are indispensable for predicting survival and treatment response. Given...
7.
Konecny G, Hendrickson A, Davidson T, Winterhoff B, Ma S, Mahner S, et al.
Gynecol Oncol
. 2021 Oct;
163(3):465-472.
PMID: 34642026
Purpose: Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting...
8.
Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al.
Ann Oncol
. 2021 Aug;
32(11):1410-1424.
PMID: 34419555
Background: Guideline recommendations for the treatment of breast cancer with low hormone receptor (HR) expression (1%-9%) are ambiguous and several studies showed more similarities with HR-negative tumors than with HR...
9.
10.
Mirza M, Benigno B, Dorum A, Mahner S, Bessette P, Barcelo I, et al.
Gynecol Oncol
. 2020 Sep;
159(2):442-448.
PMID: 32981695
Objective: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response...